CTOs on the Move

Inivata

www.inivata.com

 
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The Company`s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and backed by multiple high calibre publications. Its lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and its wider platform, which is applicable to a range of cancer types. The Company has ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.inivata.com
  • 7020 Kit Creek Road Suite 140
    Morrisville, NC USA 27560
  • Phone: 919.679.2848

Executives

Name Title Contact Details
Alan Schafer
Chief Technology Officer Profile
Charles Kesinger
Chief Information Officer Profile

Funding

Inivata raised $52.6M on 03/28/2019
Inivata raised $25M on 05/26/2020
Inivata raised $35M on 02/04/2021

Similar Companies

Velsera

Velsera is a company that connects healthcare and life sciences to reveal the true promise of precision medicine. They power this ecosystem of insight with data made actionable by AI and technology solutions that accelerate R&D, democratize omics and p...

IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.

Biotix Holdings

Biotix Holdings is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Kiadis

Kiadis Pharma is a clinical stage biopharmaceutical company focused on developing innovative and potentially life-saving therapies for blood cancer patients where pharmacological standard of care is no longer an alternative. The Company`s main focus is on the development of a cellular therapeutic that will enable partially mismatched donor stem cell transplants from family members in blood cancer patients, thus making them safe and available as the last potentially life saving option. Stem cell transplantation is currently the only potentially curative treatment available for late stage blood cancer patients; however, a standard of care matching donor is only available for half of patients who are progressing with radiation therapy and chemotherapy.

Advanced Solutions

Advanced Solutions designs and manufactures biofabrication systems for next-generation drug discovery, personalized medicine, and regenerative therapeutics.